C WorldWide Group Holding A S Sells 1,540 Shares of Edwards Lifesciences Corporation $EW

C WorldWide Group Holding A S decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 396,778 shares of the medical research company’s stock after selling 1,540 shares during the quarter. Edwards Lifesciences comprises approximately 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 28th largest holding. C WorldWide Group Holding A S’s holdings in Edwards Lifesciences were worth $31,032,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $28,000. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $26,000. NewSquare Capital LLC grew its stake in shares of Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares in the last quarter. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $27,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $29,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.29% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on EW shares. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Barclays reissued an “overweight” rating and issued a $99.00 price target (up from $95.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 price target (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Price Performance

NYSE EW opened at $82.86 on Thursday. The company has a market cap of $48.65 billion, a PE ratio of 11.92, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $87.09. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $77.72 and its two-hundred day simple moving average is $77.18.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.